Unlock the most comprehensive insights into the rapidly evolving Targeted Protein Degradation (TPD) landscape with our latest market intelligence report. Covering 382 asset-based companies and 655 active TPD assets, this report provides an in-depth analysis of PROTACs, DUB inhibitors, LYTACs, Molecular Glues, RNA degraders, and Degrader-Antibody Conjugates (DACs).

Explore cutting-edge technologies, key patents, and clinical advancements driving the next generation of targeted therapeutics. Whether you’re in drug discovery, business development, or competitive intelligence, this report is your essential guide to the future of protein degradation therapies.